Article info

Download PDFPDF

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Authors

  1. a SUNL2{at}ccf.org
  2. b FUNCHAP{at}ccf.org
  3. c SONGJ{at}ccf.org
  4. d RAYMANP{at}ccf.org
  5. e TANNENC{at}ccf.org
  6. f koj2{at}ccf.org
  7. g MCNAMAM{at}ccf.org
  8. h diazc2{at}ccf.org
  9. i (216) 445-2103 gastmanor{at}ccf.org gastmab{at}ccf.org
View Full Text

Citation

Sun L, Funchain P, Song JM, et al
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Publication history

  • Received February 2, 2018
  • Accepted March 14, 2018
  • First published May 16, 2018.
Online issue publication 
May 16, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.